Benjamin Kim, MD, MPhil

VP, Clinical Development
Vega Therapeutics
South San Francisco, California, United States

Benjamin Kim, MD, MPhil: Vice President, Clinical Development; Vega Therapeutics, Inc.

Ben is the Clinical Lead for VGA039. Previously, he served as the Medical Monitor for HAVEN 1 (Hemlibra) at Roche, Clinical Development Team Lead for the GENEr8 studies (ROCTAVIAN) at BioMarin, and VP of Clinical Development & Operations at Catalyst Biosciences (MarzAA).

Presentation(s):

• PB1311 - Prophylactic Efficacy Of VGA039, An Anti-Protein S Monoclonal Antibody, In A Novel Non-Human Primate Model Of Acquired Von Willebrand Disease

  Tuesday, June 27, 2023
  18:30 – 19:30 ET